2-1-2014

The spectrum of eye disease in hospitalized adults living with HIV, 1995-2010.

Christopher Miller

Division of Infectious Diseases, Thomas Jefferson University Hospital

William Short, MD, MPH

Division of Infectious Diseases, Thomas Jefferson University Hospital; Jefferson Medical College, Thomas Jefferson University

Lorena Perez-Povis

Division of Infectious Diseases, Thomas Jefferson University Hospital; Shannon Clinic and Shannon Medical Center

Josephine Lontok

Division of Infectious Diseases, Thomas Jefferson University Hospital

Part of the Ophthalmology Commons

Wills Eye Institute; Nemours/Al DuPont Hospital for Children

<https://jdc.jefferson.edu/medfp/123>

Recommended Citation

Miller, Christopher; Short, MD, MPH, William; Perez-Povis, Lorena; Lontok, Josephine; Fecarotta, Christopher; Liu, Mengdan; Sendeki, Jocelyn; and Belden, Katherine, "The spectrum of eye disease in hospitalized adults living with HIV, 1995-2010." (2014). *Department of Medicine Faculty Papers*. Paper 123.

<https://jdc.jefferson.edu/medfp/123>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Christopher Miller; William Short, MD, MPH; Lorena Perez-Povis; Josephine Lontok; Christopher Fecarotta; Mengdan Liu; Jocelyn Sendeki; and Katherine Belden

The Spectrum of Eye Disease in Hospitalized Adults Living with HIV, 1995–2010

Christopher Miller, MD,¹ William R. Short, MD, MPH,^{1,6} Lorena Perez-Povis, MD,^{1,2} Josephine Lontok, MD,¹ Christopher Fecarotta, MD,³ Mengdan Liu,⁴ Jocelyn Sendekci,⁵ and Katherine Belden, MD^{1,6}

Abstract

Eye disease is a well-documented complication of HIV infection. Opportunistic infections generally comprised the majority of pre-antiretroviral therapy (ART) eye complications. With the introduction of ART, opportunistic infections diminished. However, early ART regimens were cumbersome regarding side effects and pill burden, making patient compliance difficult. Newer ART regimens are better tolerated and consist of fewer pills, theoretically making compliance easier and therapy more effective. The aim of this chart review study is to examine eye disease epidemiology in HIV patients as ART has evolved. We reviewed 222 admissions at Thomas Jefferson University Hospitals for 188 patients. These cases were divided into two groups. The first group was comprised of patients admitted from 1995 through 2003, while the second group consisted of patients admitted from 2003 to 2010. Eye disease epidemiology was compared between the two groups. Our study did note a significant decrease in eye diseases caused by opportunistic infections in the 2003–2010 patient group. Noninfectious eye disease is a significant complication in this group.

Introduction

IN THE PRE-HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ERA (HAART, or ART; please note that HAART serves as a historical term for this article. We will refer to such HIV treatment regimens as “antiretroviral therapy” or ART), opportunistic infections of the eye were frequent and often severe.¹ However, the epidemiology of eye involvement in HIV has changed as a result of our ability to control HIV disease with newer ART regimens.^{2–7} The incidence and overall severity of opportunistic infectious diseases of the eye have decreased, along with other sequelae of immunosuppression.

The stark contrast in HIV eye diseases before and after the introduction of ART has been described in the literature.⁸ However, epidemiologic differences in HIV eye disease that have occurred during the ART era have not been as well established. Recent studies still estimate that approximately 40% of patients with AIDS and no evidence of infectious retinitis still demonstrate significant visual impairment.⁹ Such ongoing disease may be indirectly due to a persistent systemic inflammatory state (the hypothesized etiology of HIV retinopathy) or due to the aforementioned

increase in incidence of additional non-AIDS related comorbidities in today's HIV patients (diabetes or hypertension, for instance).

The aim of this study is to review retrospectively a population of HIV-positive hospitalized patients with eye disease over this time period of ART evolution. We then compare the epidemiology of eye disease in patients seen in the early era of ART with the more recent era of ART.

Methods

Patient population

HIV-infected adults with active ocular disease admitted as inpatients for any reason to the Wills Eye Institute and Thomas Jefferson University Hospitals between December 30, 1995 and October 31, 2010 were identified through a search of applied International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes including HIV (042, V08) and any ocular diagnosis (360–379).

An initial 422 admissions were identified. Of these, 9 charts were unavailable, 129 admissions were noted to have no active ocular diagnosis, 59 were noted to be duplicate patient

Divisions of ¹Infectious Diseases and ⁵Biostatistics, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

²Shannon Clinic and Shannon Medical Center, San Angelo, Texas.

³Wills Eye Institute, Philadelphia, Pennsylvania; and Nemours/Al DuPont Hospital for Children, Wilmington, Delaware.

⁴Center for Research in Medical Education and Health Care, Jefferson Medical College, Philadelphia, Pennsylvania.

⁶Jefferson Medical College of Thomas Jefferson University.

TABLE 1. DEMOGRAPHICS^a

Demographics	All patients (n=188)	Early ART (n=60)	Late ART (n=128)	p Value
Age (yrs) (median)	50	51	50	0.2491
Gender (% male)	68.6	73.3	66.4	0.34
Race (%)				0.032
White non-hispanic	26	15	31.2	
Black non-hispanic	68.6	81.7	62.4	
Other	5.4	3.3	6.4	
Substance abuse (%)	32.8, n=183	31.6, n=57	33.3, n=126	0.8149
Tobacco abuse (%)	29, n=183	26.3, n=57	30.2, n=126	0.5956
HIV history				
Median time (yrs) since HIV diagnosis	6, n=85	6, n=39	7.5, n=46	0.0673
Median CD4+ T-cells (cells/ μ L)	83, n=143	40, n=50	108, n=93	<0.0001
% CD4+ T-cells <200 cells/ μ L	72, n=143	88, n=50	63.4, n=93	0.0052
% Patients with HIV viral load >400 copies/mL	72.1, n=86	88.5, n=26	65, n=60	0.0259
Current antiretroviral therapy (%)	58.5	51.7	61.7	0.1922
History of opportunistic infection	47.4, n=175	72.2, n=54	36.4, n=121	<0.0001
Selected co-morbidities (%)	N=183	N=57	N=126	
Diabetes mellitus	13.7	7	16.7	0.0784
Malignancy	11.5	1.8	15.9	0.0055
Cardiovascular disease	20.8	15.8	23	0.2644
Chronic kidney disease	8.2	8.8	7.9	1
Chronic viral hepatitis	20.8	17.5	22.2	0.47

^aNot all demographic information for each patient was available.

admissions without a new ocular diagnosis, and 3 admissions did not have confirmed HIV by history or laboratory testing. These cases were excluded, leaving 222 admissions amongst 188 patients.

A retrospective chart review was conducted. Data for the study were collected from included charts. Demographic patient information collected included age, gender, race, substance abuse history, CD4+ T cells/ μ L, HIV viral load, current antiretroviral therapy, and select co-morbidities (Table 1).

Outcome

Active ocular diagnoses were recorded for each admission. Visual acuity was documented when available (160 of 188 patients had a full ophthalmologic exam with full visual acuity). All patients in the study with documented visual acuity received a full ophthalmologic exam. For the 22 patients without documented visual acuity, documentation of further ophthalmologic examination was not recorded.

Patients and their active ocular diagnoses were divided into comparison groups based on date of presentation. An "Early ART" arm of the study consisted of presentations from December 30, 1995 through June 30, 2003. A "Late ART" arm of the study consisted of presentations from July 1, 2003 through October 31, 2010.

For this study, 2003 was chosen as a separation time point between study groups. Prior to 2003, protease inhibitor (PI) regimens still proved cumbersome and triple-nucleotide reverse transcriptase inhibitor (NRTI) regimens still remained in use. In 2003 and beyond, newer, better-tolerated medications such as atazanavir, fosamprenavir, and fixed-dose combination pills such as tenofovir/emtricitabine and tenofovir/emtricitabine/efavirenz became available. Therefore, 2003 seemed a reasonable time to demarcate an "early" time frame capturing patients on first-generation PIs and NRTIs versus a "late" time frame capturing patients on modern PIs, fixed-dose combination pills, and NNRTIs.

Statistics

p Values were obtained with the unpaired *t*-test, chi-square test, or Fisher's exact test and adjusted by false discovery rate methods, when indicated.

Results

From the 222 admissions, 252 active ocular diagnoses were identified (please refer to Table 4 for a complete breakdown by anatomic location). Sixty patients were included in the early ART arm of the study, and 128 patients were included in the late ART arm (Table 1).

Immunologic and virologic comparison of the two patient groups illustrated a significantly higher median CD4+ count in the late ART patients compared with the early ART patients (108 vs. 40 cells/ μ L). The late ART group also had significantly fewer patients with uncontrolled viral load (defined as >400 copies/mL) compared with the early ART group (65% vs. 88.5% of patients). In addition, late ART patients were less likely to have had an opportunistic infection in the past (36.4% of late ART patients had a history vs. 72.2% of early ART patients).

TABLE 2. INFECTIOUS VS. NONINFECTIOUS OCULAR DIAGNOSES

	Total diagnoses (%) N=252	Early ART (%) N=77	Late ART (%) N=175	p Value
Infectious diagnosis	43	54.6	37.7	0.0129
Noninfectious diagnosis	57	45.5	62.3	

TABLE 3. MOST FREQUENT OCULAR DIAGNOSES BY EARLY AND LATE ART GROUPS

Diagnosis	Total diagnoses (%) N=252	Early ART (%) N=77	Late ART (%) N=175	p Value
Noninfectious retinopathy	13.9	18.2	12	0.4097
CMV retinitis (Fig. 1)	13.9	28.6	7.4	<0.0001
Retinal detachment (Fig. 4)	7.6	6.5	8	1
Ulcerative keratitis	7.1	3.9	8.6	0.4097
Necrotizing herpetic retinitis/viral retinitis (Fig. 2)	5.6	5.2	6.3	1
Preseptal cellulitis	3.6	3.9	3.4	1
Trauma	3.2	0	4.6	0.4097
Cataract	2.8	0	4	0.4097
Ocular syphilis	2.8	2.6	2.9	1
Cranial nerve palsy	2.8	0	4	0.4097
Conjunctivitis	2.4	2.6	2.3	1
Conjunctival hemorrhage	2.4	0	3.4	0.4097
Glaucoma	2.4	1.3	2.9	1
Noninfectious uveitis	2.4	3.9	1.7	0.7003
Endogenous endophthalmitis	1.9	1.3	2.3	1
Optic neuritis	1.9	3.9	1.1	0.4097

The late ART group of patients, however, tended to have more co-morbidities compared to the early ART patients. Most significantly, patients in the late ART group had a 15.9% prevalence of malignancy versus only a 1.8% incidence in the early ART group. Late ART patients also had a significantly higher prevalence of diabetes mellitus compared to their early ART counterparts (16.7% vs. 7% prevalence). While not statistically significant, late ART patients also tended to have a higher prevalence of cardiovascular disease and chronic viral hepatitis (Table 1).

Among the early ART patients, 77 ocular diseases were diagnosed, while 175 ocular diseases were diagnosed in the late ART group. Ocular disease in both groups combined was predominately noninfectious (57%). Ocular diagnoses were compared in early and late ART groupings. Early ART diagnoses had significantly more infectious eye disease occurrence compared to the late ART group (54.6% of cases vs. 37.7%) (Table 2).

The most frequent ocular diagnoses (from Table 4) found in the early and late ART groups were compared with *p* values calculated for the differences in prevalence (Table 3) (note that *p* values were not calculated for differences in all diagnoses from Table 4, just for the most frequent that appear in Table 3). Most notably, 28.6% of ocular disease in the early ART group was CMV retinitis (Fig. 1) compared to only 7.4% in the late ART group. This diagnosis represented the highest burden of ocular disease in early ART patients by a large margin. In contrast, the incidence of ocular disease diagnoses in the late ART group was more evenly distributed amongst a wide range of categories.

The late ART group did have a significantly higher rate of severe vision impairment, however, when visual acuity was documented. Forty-eight patients in the early ART group and 112 patients in the late ART group had visual acuity documented. While the percentage of patients with "mild" visual impairment (<20/40 but ≥20/200) was roughly equal (22.9% of early ART patients vs. 19.6% of late ART patients, *p* value of 0.64), the percentage of patients with "severe" visual impairment (<20/200) was significantly more for the late ART group (37.5% of early ART patients versus 58% of late ART patients, *p* value of 0.02).

Discussion

Ocular disease is associated with human immunodeficiency virus (HIV) infection.^{10–12} Ocular manifestations of HIV infection have been well described in the pre-ART era of HIV infection when patients frequently developed severe immunodeficiency followed by the development of opportunistic infections. Direct therapy (ganciclovir for cytomegalovirus, or CMV retinitis, for instance) for such opportunistic infections provided limited benefit in patients suffering from a progressively failing immune system.¹³

With the approval of zidovudine as the first antiretroviral therapy for HIV in 1987, the face of HIV disease began to change. The most dramatic change came in the mid-1990s with the introduction of ART, which made preservation of T-cell immunity and suppression of HIV possible. Early ART regimens, however, were inconvenient and cumbersome for patients due to high pill burdens, food restrictions, and intolerable side effects.^{2–7} Drug compliance, and therefore control of HIV disease, remained a challenge. With time, however, drugs with better tolerability, potency, and efficacy have been developed. Such developments have even made it possible to include a complete ART regimen co-formulated into one pill taken once daily. As a result, compliance and control of HIV are now much more realistic goals.

Eye disease caused by infectious agents such as *Toxoplasma gondii* (Fig. 5), varicella-zoster virus (VZV) (Fig. 3), and, most notably, CMV (Fig. 1), were disproportionately represented in HIV patients before HAART became widely available. One autopsy study from the pre-ART era found a 32% incidence of postmortem HIV-infected patients with evidence of CMV retinitis,¹⁴ and that the incidence of clinically apparent CMV retinitis in individuals with severe T-cell impairment (CD4+ <100 cells/μL) may be as high as 25%.¹⁵ Frequently, HIV-infected patients with CMV retinitis progressed to retinal detachment and severe visual impairment months after the onset of visual disturbance.

As control of HIV has improved, the incidence of opportunistic infections decreased.^{2–7,11} One epidemiologic study from 1996 to 2004 found a 92% decrease in AIDS-related mortality in HIV patients while ART utilization increased from 43% to 82%

TABLE 4. ACTIVE OCULAR DIAGNOSES BY ANATOMIC LOCATION

<i>Eye anatomic location</i>	<i>All diagnoses (n=252)</i>	<i>Early ART (n=77)</i>	<i>Late ART (n=175)</i>
<u>Adnexa/orbit</u>	44 (17.4%)	10	34
<u>Eyelids</u>	15 (5.9%)	5	10
Preseptal cellulitis	9 (3.6%)	3	6
Blepharitis (infectious)	3 (1.2%)	2	1
Ectropion	2 (0.8%)	0	2
Entropion	1 (0.4%)	0	1
<u>Orbit and surrounding tissues</u>	11 (4.4%)	1	10
Ocular invasive tumor	4 (1.6%)	0	4
Orbital cellulitis	3 (1.2%)	1	2
Thyroid ophthalmopathy/exophthalmos	2 (0.8%)	0	2
Infected eye implant	1 (0.4%)	0	1
Non-infectious frozen globe	1 (0.4%)	0	1
<u>Eyelid/orbit</u>	8 (3.2%)	0	8
Trauma	8 (3.2%)	0	8
<u>Lacrimal ducts</u>	6 (2.4%)	4	2
Dry eye syndrome	4 (1.6%)	4	0
Dacryostenosis	1 (0.4%)	0	1
Dacryostenosis (infectious)	1 (0.4%)	0	1
<u>Combined</u>	4 (1.6%)	0	4
Herpes zoster ophthalmicus	4 (1.6%)	0	4
<u>Anterior segment disease</u>	59 (23.4%)	11	48
<u>Cornea</u>	24 (9.5%)	5	19
Ulcerative keratitis	18 (7.1%)	3	15
Noninfectious	7 (2.8%)	2	5
Infectious	11 (4.4%)	1	10
Non-ulcerative keratitis	3 (1.2%)	2	1
Corneal scar	2 (0.8%)	0	2
Superficial punctate keratopathy	1 (0.4%)	0	1
<u>Lenses</u>	13 (5.2%)	2	11
Cataract	7 (2.8%)	0	7
Presbyopia	4 (1.6%)	2	2
Posterior synechiae	1 (0.4%)	0	1
Lens dislocation	1 (0.4%)	0	1
<u>Conjunctiva</u>	12 (4.8%)	2	10
Acute conjunctivitis	6 (2.4%)	2	4
Conjunctival hemorrhage	6 (2.4%)	0	6
<u>Anterior chamber</u>	7 (2.8%)	1	6
Glaucoma	6 (2.4%)	1	5
Hyphema	1 (0.4%)	0	1
<u>Pupil</u>	2 (0.8%)	0	2
Pupillary margin degeneration	1 (0.4%)	0	1
Anisocoria	1 (0.4%)	0	1
<u>Sclera</u>	1 (0.4%)	1	0
Episcleritis (infectious)	1 (0.4%)	1	0
<u>Posterior segment disease</u>	112 (44.4%)	45	67
<u>Retina</u>	107 (42.5%)	45	62
CMV retinitis	35 (13.9%)	22	13
Noninfectious retinopathy	35 (13.9%)	14	21
HIV retinopathy (Fig. 2)	23 (9.1%)	11	12
DM retinopathy	9 (3.6%)	2	7
Retinal hemorrhage	1 (0.4%)	0	1
HTN retinopathy	1 (0.4%)	1	0
Sickle cell retinopathy	1 (0.4%)	0	1
Retinal detachment	19 (7.6%)	5	14
Retinal detachment	16 (6.3%)	4	12
Proliferative vitreoretinopathy	2 (0.8%)	0	2
Retinal tear	1 (0.4%)	1	0
Necrotizing herpetic retinitis/viral retinitis	15 (5.6%)	4	11
Cryptococcal retinitis	1 (0.4%)	0	1
Lattice degeneration	1 (0.4%)	0	1
Macular hole	1 (0.4%)	0	1
<u>Vitreous</u>	1 (0.4%)	0	1
Vitreous syneresis	1 (0.4%)	0	1

(continued)

TABLE 4. (CONTINUED)

<i>Eye anatomic location</i>	<i>All diagnoses (n=252)</i>	<i>Early ART (n=77)</i>	<i>Late ART (n=175)</i>
Choroid	2 (0.8%)	0	2
Choroidal hemorrhage	1 (0.4%)	0	1
Choroidal detachment	1 (0.4%)	0	1
Retina vessels	2 (0.8%)	0	2
Retinal vein occlusion	2 (0.8%)	0	2
Anterior/posterior segment disease	18 (7.1%)	6	12
Ocular syphilis	7 (2.8%)	2	5
Panuveitis	5 (1.9%)	2	3
Retinitis	2 (0.8%)	0	2
Noninfectious uveitis	6 (2.4%)	3	3
Uveitis	1 (0.4%)	0	1
Behcet's uveitis	1 (0.4%)	0	1
Iritis	1 (0.4%)	1	0
Vitritis	2 (0.8%)	1	1
Choroiditis	1 (0.4%)	1	0
Endogenous endophthalmitis (bacterial)	5 (1.9%)	1	4
Neuro-ophthalmic	19 (7.6%)	5	14
Cranial nerves/extraocular muscles	7 (2.8%)	0	7
Cranial nerve palsy	7 (2.8%)	0	7
Noninfectious	6 (2.4%)	0	6
Infectious	1 (0.4%)	0	1
Optic nerve	5 (1.9%)	3	2
Optic neuritis	5 (1.9%)	3	2
Infectious	4 (1.6%)	2	2
Noninfectious	1 (0.4%)	1	0
Brain	7 (2.8%)	2	5
Migraine with ocular pain	3 (1.2%)	0	3
Hemianopsia	2 (0.8%)	1	1
Encephalitis with photophobia (infectious)	1 (0.4%)	1	0
Gaze preference (non-infectious)	1 (0.4%)	0	1

FIG. 1. Cytomegalovirus retinitis. This image was originally published in the Retina Image Bank ASRS. Author, Jeremy B. Gross, MD. Uploaded October 10, 2012. Copyright 2013 American Society of Retina Specialists.

FIG. 2. HIV retinopathy. This image was originally published in the Retina Image Bank ASRS. Author, Alex P. Hunyor, MD. Uploaded January 11, 2013. Copyright 2013 American Society of Retina Specialists.

over this period¹⁶ (this includes eye diseases such as CMV: several epidemiologic studies of the late 1990's estimate a 50–80% decrease in the incidence of CMV retinitis alone since the introduction of ART^{17–19}). Consequently, the incidence of non-AIDS-related mortality significantly increased over this time period.^{2–7} Today's HIV practitioners often face their most significant challenges from noninfectious co-morbidities such as coronary artery disease, osteoporosis, chronic kidney disease, hyperlipidemia, liver disease, and non-AIDS defining malignancies.

In our study, noninfectious eye disease was more common overall than infectious disease. In the early ART group, however, infections represented the majority of eye diseases that were seen. The significant decrease in opportunistic in-

fections in the late ART group supports the conclusion that ART may have been a less effective intervention in the early ART group. The median time since HIV diagnosis in the early and late groups was 6 and 7.5 years, respectively. Despite an average year and a half added exposure to HIV infection, late ART patients were far less likely to have had an opportunistic infection. One could subsequently conclude that improved efficacy of ART in the late group directly impacted the incidence of infectious eye diseases.

A bias towards an increased number of opportunistic infections in the early ART group may very well exist in this study, however. Many patients in the early ART group may have acquired their opportunistic infections prior to the

FIG. 3. Progressive outer retinal necrosis. This image was originally published in the Retina Image Bank ASRS. Author, Mallika Goyal, MD. Uploaded October 31, 2012. Copyright 2013 American Society of Retinal Specialists.

FIG. 4. Acute retinal detachment. This image was originally published in the Retina Image Bank ASRS. Author, Jeffrey G. Gross, MD. Uploaded October 12, 2012. Copyright 2012 American Society of Retina Specialists.

availability of any effective antiretrovirals. They may have subsequently survived long enough to be included in the early ART group. Many such patients may not have survived long enough, however, to be included in the late ART group. A better understanding of HIV treatment and prevention of opportunistic infections may have prevented acquisition of such infections for late ART patients and may partially ac-

count for the decreased prevalence of opportunistic infections in the late ART group.

An additional caveat exists in that HIV eye diseases that were frequently managed in the inpatient setting in the 1990s can now be managed in the outpatient setting. For example, a regimen of oral valganciclovir in combination with ART could now potentially be used to treat CMV retinitis in the outpatient setting. However, such a diagnosis would almost universally prompt an inpatient admission in the time frame captured by the early ART group. As this study only examined eye diseases in inpatients, fewer patients with true infectious eye disease may have been captured in the late ART group, since these patients may have been able to avoid hospital admission altogether.

In addition, lack of initial insurance reimbursement for PIs made their availability to patients impractical in many cases until the late 1990s. Therefore, despite the existence of PIs throughout the early ART time period, these effective HIV medications may not have been widely employed over that same time frame, and opportunistic infections may therefore have developed with greater frequency in this group.

The majority of patients with ocular disease, whether infectious or not, experienced diminished visual acuity (when documented). Patients in the late ART group were significantly more likely to have documented visual acuity ($<20/200$) as compared to early ART patients. Our data concur with other larger studies¹⁰ that also illustrate that visual impairment remains a significant problem in the HIV population, despite improved control of HIV. Emerging noninfectious eye diseases in HIV patients are likely to continue to have an impact on vision, despite improved control of HIV. HIV practitioners, who may be unaware of the potential effects of

FIG. 5. Syphilitic maculopathy. This image was originally published in the Retina Image Bank ASRS. Author, Matthew W. MacCumber, MD, PhD; co-author, Milad Hakimbash, MD. Photographer, Tara Farmer. Uploaded August 31, 2012. Copyright 2013 American Society of Retina Specialists.

FIG. 6. Toxoplasma chorioretinitis. This image was originally published in the Retina Image Bank ASRS. Author, Alex P. Hunyor, MD. Uploaded January 11, 2013. Copyright 2013 American Society of Retina Specialists.

noninfectious causes of visual impairment, may inadvertently leave evolving eye disease unaddressed.

In conclusion, ART has significantly changed the epidemiologic landscape of HIV disease. The incidence of life-threatening opportunistic infections has significantly decreased in the setting of newer, more efficacious, and better-tolerated antiretroviral drugs for those individuals who are diagnosed, who are retained in care, and who remain on ART with a suppressed viral load. Noninfectious co-morbidities are often of more pressing concern to the health of HIV patients taking modern ART regimens.

This generalization appears to be true with regard to eye disease in the HIV patient as well. Vision-threatening opportunistic infections such as CMV retinitis were commonly seen prior to the development of antiretroviral medications. Such infections still represented a significant disease burden amongst patients taking early-generation ART regimens; however, it appears that newer iterations of ART are causing a decrease in the incidence of such opportunistic eye infections. Noninfectious eye diseases now appear to be a more significant threat to vision in the late ART HIV patient.

These study data have several limitations. Most notably, this study is a small, cross-sectional examination with an inherent selection bias, since only hospitalized patients were included. These data may not reflect a true representation of eye disease in the general HIV population. Furthermore, patients without subjective eye complaints may have never received an ocular diagnosis, and therefore subclinical eye disease may not have been discovered. Also of note, some demographic information for the patients in this study was unavailable and therefore incomplete.

With these limitations in mind, we conclude that our data provide evidence of a shift in the epidemiology of HIV eye disease. Noninfectious pathology seems to be a more significant cause of visual loss in the late ART era. This observation is consistent with the shifting epidemiology of HIV morbidity and mortality in general and underscores the continued need

for routine eye care as a component of the comprehensive management of HIV infected patients.

Acknowledgments

Data from this study were collected exclusively within the Thomas Jefferson University Hospitals and Wills Eye Institute of Thomas Jefferson University.

Author Disclosure Statement

There are no commercial conflicts of interest or additional disclosures.

References

1. Sterling TR, Chaisson RE. General clinical manifestations of human immunodeficiency virus infection (including the acute retroviral syndrome and oral, cutaneous, renal, ocular, metabolic, and cardiac diseases). *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 7th Ed. Philadelphia, PA: Churchill Livingstone Elsevier, 2010; pp. 1705–1725.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. *N Engl J Med* 1998;338:853–860.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA Study: An observational study. *Lancet* 2003;362:22–27.
4. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA Study. *AIDS* 2002;16:1663–1671.
5. Buchacz K, Baker RK, Palella FJ, et al. Rate of opportunistic illnesses and CD4 cell counts at OI diagnosis in a cohort of US patients (1999–2006). Abstract. Conference on Retroviruses and Opportunistic Infections, Montreal, 2009.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. *Lancet* 2002;360: 119–129.
7. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. *JAMA* 1990;263:402–406.
8. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: Ocular diagnosis at enrollment. *Ophthalmology* 2007;114:780–786.
9. Freeman WR, Van Natta ML, Jabs D, et al. Vision function in HIV-infected individuals without retinitis; Report of the studies of ocular complications of AIDS Research Group. *Am J Ophthalmol* 2008;145:453–462.
10. Cunningham Jr ET, Margolis TP. Ocular manifestations of HIV infection. *N Engl J Med* 1998;339:236–244.
11. Jabs DA. Ocular manifestations of HIV infection. *Trans Am Ophthalmol Soc* 1995;93:623–683.
12. Sarraf D, Ernest JT. AIDS and the eyes. *Lancet* 1996;348:525–528.
13. Martin DF, Kupperman BD, Wolitz RA, et al. Oral ganciclovir for patients treated with cytomegalovirus retinitis treated with a ganciclovir implant. *NEJM* 1999;340: 1063–1070.
14. McKenzie R, Travis WD, Dolan SA, et al. The causes of death in patients with human immunodeficiency virus infection: A clinical and pathologic study with emphasis on the role of pulmonary diseases. *Medicine (Baltimore)* 1991; 70:326–343.
15. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency vi-

- rus immunosuppression. Arch Ophthalmology 1996;114: 821–827.
16. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV Outpatient Study. JAIDS 2006;43:27–34.
17. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443–1445.
18. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182–1187.
19. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleosides analogues plus indinavir in persons with immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725–733.

Address correspondence to:

Dr. Christopher Miller

Division of Infectious Diseases, Suite 1020

Thomas Jefferson University Hospital

1015 Chestnut Street

Philadelphia PA 19107

E-mail: christopher.miller@jeffersonhospital.org